Atrial fibrillation and the use of oral bisphosphonates.

Ther Clin Risk Manag · 2011 · PMC3071350 · PMID 21479144

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

3 Reanalysis of clinical trial data of alendronate (FIT studies) showed a trend towards an increased risk of serious (though not all) AF events. 4 However, analysis of adverse cardiovascular events in approximately 15,000 postmenopausal women in Phase III clinical trials of risedronate demonstrated no increased risk of AF, classified either as an adverse or serious adverse eve

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.